Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126041 | 0.85 | EPHX2 (0.43) | EPHX2ABCG2MEN1KMT2AMAPT | |
| SCHEMBL7117443 | 0.82 | EPHX2 (0.62) | EPHX2ABCG2MEN1KMT2AMAPT | |
| SCHEMBL7122006 | 0.80 | EPHX2 (0.54) | EPHX2ABCG2MEN1KMT2AMAPT | |
| SCHEMBL7128452 | 0.80 | ABCG2 (0.46) | ABCG2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL7126929 | 0.77 | EPHX2 (0.55) | EPHX2ABCG2MEN1KMT2AMAPT | |
| SCHEMBL7125162 | 0.74 | ABCG2 (0.57) | EPHX2ABCG2KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL7119901 | 0.73 | ABCG2 (0.47) | ABCG2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL7125078 | 0.72 | HDAC3 (0.45) | ABCG2MEN1KMT2AMAPTKDM4E | |
| Iodide SCHEMBL7122705 | 0.71 | MAPT (0.40) | ABCG2MEN1KMT2AMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL7130682 | 0.70 | HIF1A (0.52) | EPHX2MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | EPHX2 354/4885ABCG2 639/4885MEN1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.